ZED1227

ZED1227
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name Methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(1-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate;
PubChem CID	168775562;
Chemical and physical data
Formula	C26H36N6O6
Molar mass	528.610 g·mol−1

ZED1227 is a transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for celiac disease^[1]^[2] and nonalcoholic steatohepatitis.^[3]

References[edit]

^ Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari; Langhorst, Jost; Hovde, Øistein; Lähdeaho, Marja-Leena; Fusco, Stefano; Schumann, Michael; Török, Helga P.; Kupcinskas, Juozas; Zopf, Yurdagül; Lohse, Ansgar W.; Scheinin, Mika; Kull, Karin; Biedermann, Luc; Byrnes, Valerie; Stallmach, Andreas; Jahnsen, Jørgen; Zeitz, Jonas; Mohrbacher, Ralf; Greinwald, Roland (1 July 2021). "A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease". New England Journal of Medicine. 385 (1): 35–45. doi:10.1056/NEJMoa2032441. hdl:10852/92293. PMID 34192430. S2CID 235697132.
^ Büchold, Christian; Hils, Martin; Gerlach, Uwe; Weber, Johannes; Pelzer, Christiane; Heil, Andreas; Aeschlimann, Daniel; Pasternack, Ralf (17 May 2022). "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease". Cells. 11 (10): 1667. doi:10.3390/cells11101667. PMC 9139979. PMID 35626704.
^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 3 December 2023.